- Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
Edoardo Francini et al, 2018, Clinical Genitourinary Cancer CrossRef - Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysis
Myungsun Shim et al, 2019, Scientific Reports CrossRef - Have we found an optimal sequence in the treatment of metastatic castrationally-resistant prostate cancer?
Tomáš Svoboda, 2018, Onkologie CrossRef